Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib Neoadjuvant Therapy for Resectable EGFR-Mutant NSCLC
ChiCTR2500108911Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib in EGFR-mutated non-small cell lung cancer, sponsored by Qilu Hospital of Shandong University. Primary endpoints: Major pathological response rate (MPR) and TNM downstaging rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2500108911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108911.